Phase 3Completed

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin

Sponsor
Regeneron Pharmaceuticals (Industry)
Enrollment
355 enrolled
Conditions
Hypercholesterolemia
Interventions
Alirocumab; Atorvastatin; Ezetimibe; Rosuvastatin; Placebo
Ages
adults, older adults
Registry
NCT01730040

Full record on ClinicalTrials.gov

From the registry

This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).

Primary outcomes

  • Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started